Leukemia Treatment Breakthrough

Adding Rituxan to standard chemotherapy for chronic lymphocytic leukemia raises three-year survival to 65% and is now the gold standard therapy for most patients.

Click here to read the full story.

Post a Comment

Enter the words shown above Enter the numbers you hear
Refresh Image Audio Help
No comments yet!

The Health News section does not provide medical advice, diagnosis or treatment. See additional information.

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.